Inventor · disambiguated record
Jesse Damsker
Also filed as: DAMSKER JESSE
8 granted patents·11 pending applications·25 citations·filing 2012–2025
84Inventor score
Top patents by PatentIndex Score
19 records- 0194US11471471B2Aqueous oral pharmaceutical suspension compositionsREVERAGEN BIOPHARMA INC·Filed 2022·Granted Oct 18, 2022·3 cites·21 claims
- 0294US11382922B2Aqueous oral pharmaceutical suspension compositionsREVERAGEN BIOPHARMA INC·Filed 2020·Granted Jul 12, 2022·4 cites·26 claims
- 0393US10799514B2Non-hormonal steroid modulators of NF-kappa beta for treatment of diseaseREVERAGEN BIOPHARMA INC·Filed 2016·Granted Oct 13, 2020·6 cites·18 claims
- 0491US12201639B2Aqueous oral pharmaceutical suspension compositionsREVERAGEN BIOPHARMA INC·Filed 2022·Granted Jan 21, 2025·1 cites·14 claims
- 0591US11479541B1Acid addition salts, compositions, and methods of treating thereofPIONEURA CORP·Filed 2022·Granted Oct 25, 2022·3 cites·4 claims
- 0686US11690853B2Non-hormonal steroid modulators of NF-κβ for treatment of diseaseREVERAGEN BIOPHARMA INC·Filed 2020·Granted Jul 4, 2023·1 cites·13 claims
- 0784US2025205251A1Aqueous oral pharmaceutical suspension compositionsREVERAGEN BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 0883US10464967B2Non-hormonal steroid modulators of NF-κβ for treatment of diseaseREVERAGEN BIOPHARMA INC·Filed 2012·Granted Nov 5, 2019·7 cites·4 claims
- 0978US2024307411A1Non-hormonal steroid modulators of nf-kappa beta for treatment of diseaseREVERAGEN BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1074US2020148717A1Non-hormonal steroid modulators of nf-kappa beta for treatment of diseaseREVERAGEN BIOPHARMA INC·Filed 2019·Application pending·0 cites
- 1172US2024139210A1Treatment of nf-kb-mediated diseaseREVERAGEN BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1271US2022324902A1Non-hormonal steroid modulators of nf-kappa beta for treatment of diseaseREVERAGEN BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 1369US2025145657A1Non-hormonal steroid modulators of nf-kappa beta for treatment of diseaseREVERAGEN BIOPHARMA INC·Filed 2025·Application pending·0 cites
- 1466US2022184098A1Treatment of nf-kb-mediated diseaseREVERAGEN BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 1566US2024299416A1TREATMENT OF NF-kB-MEDIATED DISEASEREVERAGEN BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 1666US2024226117A1Treatment of congenital adrenal hypoplasiaREVERAGEN BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 1764US2024376071A1Acid addition salts, compositions, and methods of treating thereofPIONEURA CORP·Filed 2024·Application pending·0 cites
- 1863US11661409B1Acid addition salts, compositions, and methods of treatingPIONEURA CORP·Filed 2022·Granted May 30, 2023·0 cites·6 claims
- 1950US2023002439A1Crystalline forms of vamoroloneREVERAGEN BIOPHARMA INC·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jesse Damsker files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →